[go: up one dir, main page]

AR029626A1 - Derivados de acido carbamico, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen - Google Patents

Derivados de acido carbamico, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen

Info

Publication number
AR029626A1
AR029626A1 ARP000101797A ARP000101797A AR029626A1 AR 029626 A1 AR029626 A1 AR 029626A1 AR P000101797 A ARP000101797 A AR P000101797A AR P000101797 A ARP000101797 A AR P000101797A AR 029626 A1 AR029626 A1 AR 029626A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
hydrogen
phenyl
trifluoromethyl
lower alkoxy
Prior art date
Application number
ARP000101797A
Other languages
English (en)
Inventor
Konrad Bleicher
Vincent Mutel
Eric Vieira
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR029626A1 publication Critical patent/AR029626A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C07C233/91—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated with carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/10—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups being part of any of the groups, X being a hetero atom, Y being any atom, e.g., N-acyl-thiocarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se refiere a compuestos de formula 1 en donde R1 significa hidrogeno o alquilo inferior; R2, R2' significan, independientemente entre sí, hidrogeno, alquilo inferior, alcoxilo inferior, halogeno o trifluorometilo; X significa O, S o dos átomos de hidrogeno que no forman un puente; A1 / A2 significan, independientemente entre sí, fenilo o un heterociclo de 6 miembros que contiene 1 o 2 átomos de nitrogeno; B es un grupo de Formula 2 en donde R3 significa alquilo inferior, alquenilo inferior, alquinilo inferior, bencilo, alquilo inferior-cicloalquilo, alquilo inferior-ciano, alquilo inferior-piridinilo, alquilo inferior-alcoxilo inferior-fenilo, alquilo inferior-fenilo, el cual está opcionalmente sustituido con alcoxilo inferior o fenilo, el cual esta opcionalmente sustituido mediante alcoxilo inferior o alquilo inferior-tienilo, cicloalquilo, alquilo inferior-trifluorometilo o alquilo inferior-morfolinilo; Y significa -O-, -S- o un enlace; Z significa -O- o -S-; o B es un grupo heterocíclico de 5 miembros, de formulas3, 4, 5 o 6 en donde R4 y R5 significan hidrogeno, alquilo inferior, alcoxi inferior, ciclohexilo, alquilo inferior-ciclohexilo o trifluorometilo, con la condicion de que por lo menos uno de R4 o R5 tiene que ser hidrogeno; así como sus sales farmacéuticamente aceptables. Estos compuestos pueden emplearse para el control o prevencion de trastornos neurologicos agudos y/o cronicos tales como la funcion cerebral restringida ocasionada por operaciones de bypass o trasplantes, pobre suministro sanguíneo al cerebro, lesiones de la médula espinal, lesiones de la cabeza, hipoxia causada por el embarazo, paro cardíaco, hipoglucemia, enfermedad de Alzheimer, corea de Huntington, ALS, demencia causada por el SIDA, lesiones del ojo, retinopatía, trastornos cognitivos, déficits de memoria, esquizofrenia, parkinsonismo idiopático o parkinsonismo causado por medicamentos así como también condiciones que conducen a funciones con deficiencia de glutamato, tales como p.ej., espasmos musculares, convulsiones, migrana, incontinencia urinaria, adiccion a la nicotina, psicosis, adiccion a los opiáceos, ansiedad, vomitos, dolor agudo y cronico, disquinesis y depresion.
ARP000101797A 1999-04-20 2000-04-18 Derivados de acido carbamico, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen AR029626A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99107843 1999-04-20

Publications (1)

Publication Number Publication Date
AR029626A1 true AR029626A1 (es) 2003-07-10

Family

ID=8238006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101797A AR029626A1 (es) 1999-04-20 2000-04-18 Derivados de acido carbamico, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen

Country Status (32)

Country Link
US (2) US6462198B1 (es)
EP (1) EP1171423B1 (es)
JP (1) JP3751825B2 (es)
KR (1) KR100497889B1 (es)
CN (1) CN1228337C (es)
AR (1) AR029626A1 (es)
AT (1) ATE286875T1 (es)
AU (1) AU776344B2 (es)
BR (1) BR0009885A (es)
CA (1) CA2367368C (es)
CO (1) CO5160347A1 (es)
CZ (1) CZ20013736A3 (es)
DE (1) DE60017376T2 (es)
ES (1) ES2234601T3 (es)
HK (1) HK1045683B (es)
HR (1) HRP20010761A2 (es)
HU (1) HUP0201005A3 (es)
IL (1) IL145665A (es)
MA (1) MA26781A1 (es)
MY (1) MY126586A (es)
NO (1) NO20015064D0 (es)
NZ (1) NZ514487A (es)
PE (1) PE20010039A1 (es)
PL (1) PL352825A1 (es)
PT (1) PT1171423E (es)
RU (1) RU2248349C2 (es)
SI (1) SI1171423T1 (es)
TR (1) TR200103010T2 (es)
TW (1) TW593241B (es)
WO (1) WO2000063166A1 (es)
YU (1) YU73001A (es)
ZA (1) ZA200107837B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
IT1318636B1 (it) * 2000-07-21 2003-08-27 Roberto Pellicciari Derivati dell'acido 2- o 3- tenoico ad attivita' antagonista deirecettori del glutammato.
RU2345076C2 (ru) * 2002-12-23 2009-01-27 Ф.Хоффманн-Ля Рош Аг ОКСАЗОЛЫ В КАЧЕСТВЕ УСИЛИТЕЛЕЙ mGluR1
AU2004263871B2 (en) 2003-08-06 2011-07-14 Senomyx, Inc. T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
JP2007501244A (ja) * 2003-08-06 2007-01-25 ファイザー・プロダクツ・インク 神経変性障害治療用オキサゾール化合物
RU2006111093A (ru) * 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
US20050222227A1 (en) * 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
ES2329063T3 (es) * 2004-08-09 2009-11-20 Glaxo Group Limited Compuestos que potencian el receptor de glutamato y sus usos en medicina.
AU2006210513C1 (en) 2005-02-04 2012-10-25 Senomyx, Inc. Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
TWI425917B (zh) 2006-04-21 2014-02-11 Senomyx Inc 包含高度鮮味風味劑之可食用組合物及其製造方法
EP2083811B1 (en) 2006-11-22 2016-10-26 Clinical Research Associates, LLC Methods of treating down's syndrome, fragile x syndrome and autism
US20080262066A1 (en) * 2007-04-20 2008-10-23 Green Cross Corporation Azole Derivatives as Cannabinoid CB1 Receptor Antagonists
PT2178858E (pt) 2007-08-02 2012-02-24 Recordati Ireland Ltd Novos compostos heterocíclicos como antagonistas de mglu5
EP2093234A1 (en) 2008-02-08 2009-08-26 Nutrinova Nutrition Specialties & Food Ingredients GmbH Oligopeptides for use as taste modulators
TWI429404B (zh) 2008-03-03 2014-03-11 Senomyx Inc 異山梨醇衍生物及彼等作為風味改良劑、促味劑及促味增強劑之用途
EP2393780A1 (en) 2009-02-04 2011-12-14 Recordati Ireland Limited Heterocyclic derivatives as m-glu5 antagonists
WO2011029633A1 (en) 2009-09-14 2011-03-17 Recordati Ireland Limited Heterocyclic mglu5 antagonists
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
ES2492694T3 (es) 2010-07-09 2014-09-10 Recordati Ireland Limited Nuevos compuestos espiroheterocíclicos como antagonistas de mGlu5
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
CN107592813A (zh) 2014-11-19 2018-01-16 伊缪诺金公司 用于制备细胞结合剂‑细胞毒性剂缀合物的方法
WO2017121693A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte thiazol- und thiadiazolamide und ihre verwendung
CN108601848A (zh) 2016-02-05 2018-09-28 伊缪诺金公司 用于制备细胞结合剂-细胞毒性剂缀合物的有效方法
AU2017311691B2 (en) 2016-08-18 2021-12-02 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
CN116034103B (zh) * 2020-09-07 2025-05-13 日产化学株式会社 1,3,4-噁二唑-2-胺化合物的制造方法
WO2024134942A1 (ja) 2022-12-22 2024-06-27 株式会社日本ファインケム ２－アミノ－５置換－１，３，４－オキサジアゾールの製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073566A (en) * 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
GB9626151D0 (en) 1996-12-17 1997-02-05 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
BR0009885A (pt) 2002-01-22
PE20010039A1 (es) 2001-01-29
CO5160347A1 (es) 2002-05-30
EP1171423B1 (en) 2005-01-12
HUP0201005A3 (en) 2004-12-28
NZ514487A (en) 2004-01-30
CN1228337C (zh) 2005-11-23
PL352825A1 (en) 2003-09-08
KR100497889B1 (ko) 2005-06-29
IL145665A (en) 2005-09-25
ES2234601T3 (es) 2005-07-01
KR20010108518A (ko) 2001-12-07
WO2000063166A1 (en) 2000-10-26
HK1045683B (zh) 2006-02-03
US20020091150A1 (en) 2002-07-11
ZA200107837B (en) 2002-12-23
RU2248349C2 (ru) 2005-03-20
US6462198B1 (en) 2002-10-08
MY126586A (en) 2006-10-31
AU776344B2 (en) 2004-09-02
JP2002542229A (ja) 2002-12-10
PT1171423E (pt) 2005-05-31
HRP20010761A2 (en) 2002-12-31
DE60017376T2 (de) 2006-03-02
CZ20013736A3 (cs) 2002-03-13
EP1171423A1 (en) 2002-01-16
ATE286875T1 (de) 2005-01-15
CA2367368C (en) 2009-09-01
SI1171423T1 (en) 2005-06-30
NO20015064L (no) 2001-10-18
CN1347406A (zh) 2002-05-01
US6596743B2 (en) 2003-07-22
TR200103010T2 (tr) 2002-05-21
JP3751825B2 (ja) 2006-03-01
MA26781A1 (fr) 2004-12-20
HUP0201005A2 (hu) 2002-07-29
YU73001A (sh) 2004-09-03
HK1045683A1 (en) 2002-12-06
CA2367368A1 (en) 2000-10-26
IL145665A0 (en) 2002-06-30
TW593241B (en) 2004-06-21
DE60017376D1 (de) 2005-02-17
AU4749200A (en) 2000-11-02
NO20015064D0 (no) 2001-10-18

Similar Documents

Publication Publication Date Title
AR029626A1 (es) Derivados de acido carbamico, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen
AR016129A1 (es) Compuestos derivados de 5h-tiazolo[3,2-a]pirimidina; su uso, un procedimiento para prepararlos, medicamentos que los contienen y compuestos utiles comointermediarios
CO5680434A2 (es) 2,4-pirimidinadiaminas utiles en el tratamiento de enfermedades neoplasticas, desordenes del sistema inmune e inflamatorios
PE20040974A1 (es) Compuestos de amida de acido carboxilico con efecto antagonico de la hcm, medicamentos que los contienen y procedimientos para su preparacion
PE20210040A1 (es) Moduladores de la via de estres integrada
ES2184772T3 (es) Derivados de bifenilo, procedimiento para su preparacion y su utilizacion como medicamentos.
PE20050896A1 (es) Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos
PE20050429A1 (es) Derivados de 2-fenilamino-4-amino-pirimidina como inhibidores de quinasa, composicion farmaceutica que los contiene y proceso de preparacion
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
AR043038A1 (es) Compuestos de pirazolotriazina y usos de los mismos
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20040583A1 (es) Nuevos derivados de benzimidazol
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
DE69328901D1 (de) 1-piperazino-1,2-dihydroindenderivate
AR047160A1 (es) Compuestos moduladores de cb1
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
AR049696A1 (es) Derivados de indol
PE20001088A1 (es) Compuestos derivados de tetrahidrobenzazepina
AR058984A1 (es) Derivados de ciclohexil piperazinil metanona
CO5200757A1 (es) Derivados de 4-indol benzamidas con actividad contra la osteoporosis, sus sales farmaceuticamente aceptables y composiciones farmaceuticas que los contienen
PE135299A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona
UY24482A1 (es) Quinoxalinadionas
PE20030867A1 (es) Derivados de quinazolinona
AR021662A1 (es) Derivados de la piperazina, proceso para prepararlos. las composiciones farmaceuticas que los contienen y la utilizacion de las mismas como medicamentoso para la preparacion de medicamentos
NZ217432A (en) 3-amino-dihydrobenzo(b)pyran derivatives; sulphur analogues and pharmaceutical compositions

Legal Events

Date Code Title Description
FB Suspension of granting procedure